Status:

TERMINATED

Novel Adenosine-independent Index of Coronary Artery Stenosis Severity Resting Flow Reserve

Lead Sponsor:

Columbia University

Conditions:

Coronary; Ischemic

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This study will enroll patients who are referred for coronary angiography and require physiological assessment to see if the lesion can be treated as per the local standard of care. Approximately 92 p...

Detailed Description

Fractional flow reserve (FFR) measurement by under hyperemic conditions has become the invasive gold standard for determining the physiologic extent of cardiac ischemia, and which has been validated i...

Eligibility Criteria

Inclusion

  • Age ≥ 18 years.
  • Patient provides signed written informed consent before any study-specific procedure.
  • Undergoing coronary angiography, for silent ischemia, stable angina, acute coronary syndrome, or other acceptable indication per the local standard of care.
  • Angiographically 40%-90% stenosis present in at least one native coronary artery.
  • Undergoing physiological assessment for standard clinical or diagnostic indications

Exclusion

  • Aorto-ostial lesion location within 3 mm of the aorta junction (both right and left).
  • Left main stenosis
  • Vessel(s) and lesion(s) not amenable for percutaneous coronary intervention (PCI) , for example diffuse disease.
  • Saphenous vein graft, chronic total occlusion
  • Haemodynamic instability at the time of intervention (heart rate\<50 beats per minute, systolic blood pressure \<90mmHg), balloon pump
  • Currently participating in another clinical study that interferes with study results.
  • Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year following index procedure.
  • Any other medical condition that in the opinion of the investigator will interfere with patient safety or study results.
  • High degree A-V block, sinus node disease.
  • Asthma/Chronic obstructive pulmonary disease (COPD) with active wheeze
  • Known hypersensitivity to adenosine
  • ST-Elevation Myocardial Infarction (STEMI) within 48 hours.

Key Trial Info

Start Date :

October 20 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 2 2018

Estimated Enrollment :

5 Patients enrolled

Trial Details

Trial ID

NCT03461705

Start Date

October 20 2017

End Date

August 2 2018

Last Update

February 7 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Columbia University

New York, New York, United States, 10032

Novel Adenosine-independent Index of Coronary Artery Stenosis Severity Resting Flow Reserve | DecenTrialz